You are here: Industry Insights > ADC

News List

Antibody-Drug Conjugates - Lessons Learned Neeta Ratanghayra
May 20, 2022
Antibody-drug conjugates (ADCs) have made significant progress in tumor therapy and show a promising future.
Weekly Pharma News Review | PharmaSources.com (March 28 to April 1) PharmaSources.com
April 07, 2022
The failure of Phase III clinical trials targeting the popular target TIGIT monoclonal antibody has once again put tumor immunotherapy on the radar this week. The pharma news review of this week from March 28 to April 1 covers a total of 25 pieces of news
ADC vs PDC-- Status Quo of the R&D of ADC-PDC Drug in China and the World PharmaSources/zhulikou431
November 15, 2021
With the sustained investment in China's pharmaceutical industry and the growing attraction of China's pharmaceutical market to global innovative drugs, more projects of innovative drugs have added the listing in China as a necessary part.
A New Target in ADC: Nectin-4 PharmaSources/Yefenghong
September 14, 2021
Recently, the application for clinical trail of Mabwell's ADC drug (9MW2821) targeting Nectin-4 has been accepted by NMPA. It is the first time that domestic enterprise enters the IND stage with the same target drug.
Breaking News! The Second ADC Approved for Marketing in China PharmaSources/Xiaoyaowan
May 21, 2020
According to the NMPA website on May 13, the marketing application for Brentuximab Vedotin Injection filed by Takeda Pharmaceutical in China has been reviewed and approved, to become the second ADC approved for marketing in China.
Second ADC Therapeutic Drug Was Approved for Marketing in China CPhI.CN
May 14, 2020
Takeda Pharmaceutical's application of vebutuximab for injection has been approved and became the second ADC drug approved in the Chinese market.
Samsung Biologics presents business updates at 2025 J.P. Morgan Healthcare Conference PRNewswire
January 15, 2025
Samsung Biologics (KRX: 207940.KS) announced its latest business achievements and 2025 outlook at the 43rd J.P. Morgan Healthcare Conference, which was held in San Francisco between January 13-16.
Samsung Biologics extends collaboration with LigaChem Biosciences for ADC development PRNewswire
January 09, 2025
Samsung Biologics (KRX: 207940.KS) announced to extend collaboration with LigaChem Biosciences (KOSDAQ: 141080) to provide antibody-drug conjugate (ADC) services.
Immuno-Oncology: Current Market Landscape and Future Trends（2） Neeta Ratanghayra
September 18, 2024
CAR-T Therapy & Antibody–Drug Conjugates.
Lepu Biopharma Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange PharmaSources.com
February 18, 2022
The biopharmaceutical company focusing on oncology therapeutics - Lepu Biopharma Co., Ltd. ("Lepu Biopharma" or the "Company", stock code: 2157), today announced the proposed listing...

Previous page 1 2 3 4 5 6 7 8 9 10 Next page